The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Measuring treatment response rates in multiple myeloma
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the new methods used to measure treatment response in multiple myeloma (MM). Minimum residual disease (MRD) has been the main method in recent years, and it’s the next frontier in MM. The main tools used are multicolour flow cytometry and next-generation sequencing. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
